ライフサイエンスコーパス: eligible patients had

1 Eligible patients had a clinical diagnosis of achondroplasia,

2 Eligible patients had a confirmed acute hepatic porphyria dia

3 Eligible patients had a documented mIDH1 tumour based on loca

4 Eligible patients had a haematological malignancy (leukaemia,

5 Eligible patients had a National Early Warning score of 2 poi

6 Eligible patients had a streptococcal PJI that was managed wi

7 Eligible patients had a urinary albumin-to-creatinine ratio (

8 Eligible patients had active ankylosing spondylitis, fulfille

9 Eligible patients had adequate end-organ function, an Eastern

10 Eligible patients had an Eastern Cooperative Oncology Group p

11 Eligible patients had atrial fibrillation, CHA(2)DS(2)-VASc (

12 Eligible patients had been enrolled at one centre in the AURA

13 Eligible patients had biopsy-proven oesophageal cancer that w

14 Eligible patients had clinical onset after age 18 years, 36 o

15 Eligible patients had CLL, were previously treated, were aged

16 Eligible patients had confirmed colonic disease with duration

17 Eligible patients had Eastern Cooperative Oncology Group perf

18 Eligible patients had FIP1L1-PDGFRA-negative HES, experienced

19 Eligible patients had had laboratory-confirmed EVD and had th

20 Eligible patients had hematologic malignancies treatable by a

21 Eligible patients had HER2-positive advanced gastric cancer a

22 Eligible patients had histologically confirmed localised pros

23 Eligible patients had histologically confirmed relapsed or re

24 Eligible patients had HIV-1 RNA concentrations of at least 10

25 Eligible patients had IVT started within 4.5 hours of stroke

26 Eligible patients had Lansky (if aged <=16 years) or Karnofsk

27 Eligible patients had MBC with measurable disease and germlin

28 Eligible patients had measurable disease (per RECIST version

29 Eligible patients had measurable or evaluable non-measurable

30 Eligible patients had metastatic prostate cancer and a PSA le

31 Eligible patients had metastatic renal cell carcinoma (RCC),

32 Eligible patients had moderate-to-very-severe COPD and at lea

33 Eligible patients had multiple myeloma and had relapsed or we

34 Eligible patients had newly diagnosed glioblastoma confirmed

35 Eligible patients had non-cystic fibrosis bronchiectasis, had

36 Eligible patients had previously untreated acute myeloid leuk

37 Eligible patients had previously untreated, histologically co

38 Eligible patients had progressed on or after, or been intoler

39 Eligible patients had recurrent measurable LGSOC after >= 1 p

40 Eligible patients had submassive or massive pulmonary embolis

41 Eligible patients had to have completed the SIROCCO or CALIMA

42 Eligible patients had two functioning kidneys and a preoperat

43 Eligible patients had untreated chronic lymphocytic leukaemia

44 Of the 331 patients enrolled during 2005 to 2010, 321 eligible patients had central histopathologic review.

45 Additionally, eligible patients had at least one of the following within th

46 Patients and Methods Eligible patients had locally advanced or metastatic ccRCC th

47 For the dose-escalation phase, eligible patients had histologically or cytologically confirm

48 For the basket dose-expansion phase, eligible patients had advanced or metastatic solid tumours or

49 All patients were tested for CFTR genotype at screening; eligible patients had to have the F508del-CFTR mutation on bo

50 double-blind, parallel-group, randomised, controlled trial, eligible patients had COPD, post-bronchodilator forced expira